Enveric Biosciences, Inc. 8-K

What Happened

• Enveric Biosciences, Inc. (ENVB) filed an 8-K reporting actions taken at and before its 2026 Annual Meeting of Stockholders and Board approvals. The Company held its annual meeting on May 28, 2026 (record date March 30, 2026); 991,828 shares (52.54% of outstanding common stock) were present or represented, constituting a quorum.
• The Board also approved new standard forms of equity awards on May 22, 2026: a Restricted Stock Unit Agreement (RSU Agreement) and a Restricted Stock Award Agreement (RSA Agreement) under the Company’s 2020 Long-Term Incentive Plan. The RSU form provides four‑year, time‑based vesting (25% at one year, then monthly installments), settlement on change in control or termination (subject to Section 409A), full vesting on a change in control and limited acceleration for qualifying terminations; the RSA form vests on a specified date subject to continued service and includes customary forfeiture and transfer restrictions.

Key Details

• Board/Director elections (each elected to serve until 2027 annual meeting):
  • Michael Webb: 564,143 For / 37,590 Withheld / 390,095 Broker non‑votes
  • George Kegler: 531,522 For / 70,211 Withheld / 390,095 Broker non‑votes
  • Frank Pasqualone: 531,937 For / 69,796 Withheld / 390,095 Broker non‑votes
  • Marcus Schabacker, M.D., Ph.D.: 566,038 For / 35,695 Withheld / 390,095 Broker non‑votes
  • Joseph Tucker, Ph.D.: 565,386 For / 36,347 Withheld / 390,095 Broker non‑votes
  • Sheila DeWitt, Ph.D.: 565,534 For / 36,199 Withheld / 390,095 Broker non‑votes
• Advisory and corporate proposals:
  • Say‑on‑Pay (advisory): 569,552 For / 26,884 Against / 5,297 Abstentions / 390,095 Broker non‑votes (approved)
  • Reverse Stock Split authorization (Board discretion to effect 1‑for‑5 to 1‑for‑15): 793,344 For / 190,175 Against / 8,309 Abstentions (approved)
  • Increase authorized common stock from 100,000,000 to 5,000,000,000: 427,158 For / 555,147 Against / 9,523 Abstentions (not approved)
  • Auditor ratification (CBIZ CPAs P.C.): 960,728 For / 19,347 Against / 11,753 Abstentions (approved)

Why It Matters

• The approved reverse split authorization gives the Board flexibility to reduce outstanding share count (1‑for‑5 to 1‑for‑15) if it chooses — a step often used to raise per‑share market price or meet listing requirements. Shareholders rejected the large increase in authorized shares, which limits the Board’s ability to issue additional shares without further approval.
• Adoption of standardized RSU and RSA forms signals the Company will continue equity‑based compensation for executives and directors; the RSU vesting and change‑in‑control provisions are important for understanding potential future dilution and executive retention outcomes.
• Say‑on‑Pay passed, indicating shareholder support for executive compensation as disclosed, and ratification of the auditor ensures continuity in external financial oversight.